CEO Francis Creighton to present UN&UP’s ThromBot at the LSI USA’26

We are excited to announce that our CEO, President, & Founder Dr. Francis Creighton has been selected to present our ThromBot technology at the most anticipated med-tech conference LSI USA ’26 this March 16–20 in Dana Point, California.

UN&UP’s ThromBot is a magnetically guided thrombectomy platform designed to safely treat medium vessel occlusions in small, tortuous cerebral arteries.

ThromBot uses a compact external magnet to actuate a rotational distal tip and magnetically enabled microwire, enabling small, highly trackable over-the-wire devices to access anatomy that large, stiff systems often cannot reach. The platform combines concurrent low-dose thrombolytic infusion with aspiration to accelerate clot clearance and remove embolic debris. By expanding safe distal access and enabling radial-friendly procedures, ThromBot aims to double thrombectomy eligibility and grow the U.S. market opportunity to more than $7B.

Our recent significant achievements include:
• Raised $12M in non-dilutive funding since 2019 through NIH SBIR grants and NIH I-Corps, Blueprint, and Breakthrough Technology awards.
• Targeted a large and growing market opportunity, with MeVOs representing a $4B+ U.S. segment and a combined MeVO and LVO opportunity approaching $7B.
• Expanded clinical scope with a system designed to enable radial-first thrombectomy for medium vessel occlusions, addressing distal anatomy where current large-profile systems often struggle.
• Advanced a novel magnetically enabled over-the-wire catheter architecture, with profiles as small as 1 mm, 3D localization, clot-face and flow sensing, force-controlled navigation, directed agent delivery, and concurrent aspiration.
• Engaged in early partnership discussions with a major C-arm manufacturer to integrate 3D localization and imaging for streamlined navigation visualization, and workflow.
• Conducted an FDA Pre-Sub, completed preclinical prototypes, initiated in vivo animal efficacy studies, identified 510(k) predicates, and established potential eligibility for the FDA Breakthrough Devices Program.
• Built a strong clinical KOL network, including collaborators from Mayo Clinic, UC San Diego, University of Virginia, Washington University in St. Louis, Royal Melbourne Hospital, and UMass Memorial Health.

Connect with our CEO Francis Creighton onsite at LSI’26 to learn more about UN&UP.